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N-(2-Hydroxypropyl)methacrylamide (HPMA) is a water soluble monomer used in the synthesis of
biocompatible and non-immunogenic polymers. In particular, poly(HPMA) can be exploited to sterically
stabilize nanoparticles (NPs) suitable for the delivery of lipophilic therapeutics without the concerns
related to the use of the polyethylene glycol (PEG), such as allergic reactions and the accelerated blood
clearance eﬀect. In addition, the use of the ring opening polymerization (ROP) of a lactone in the
presence of an initiator that bears a double bond and a hydroxyl group is a promising way (the so called
“macromonomer method”) to produce oligoester-based monomers and, in turn, to obtain biodegradable
NPs via free radical polymerization. However, HPMA cannot be used as initiator being a secondary
alcohol and thus hampering the control over the polymer molecular weight (MW). For this reason, in this
work, a novel class of amphiphilic block copolymers that consists of a poly(HPMA) backbone and several
short oligo(3-caprolactone) side chains were produced via the adoption of the reversible addition–
fragmentation chain transfer (RAFT) polymerization and the “inversion” of the macromonomer method.
The oligoester was ﬁrst synthesized via the ROP of 3-caprolactone in the presence of a primary alcohol
and then attached to HPMA using a succinic acid unit as spacer. The NPs obtained via the self-assembly
of these novel block copolymers are designed to degrade into completely water soluble poly(HPMA)
chains with a MW lower than the threshold value for the renal excretion. The cytotoxicity of these novel
carriers and their ability to load trabectedin, a hydrophobic anticancer therapeutic, were assessed.1. Introduction
Polymeric nanoparticles (NPs) are colloidal nano-assemblies
widely adopted in medicine for the delivery of lipophilic ther-
apeutics. They can be produced via diﬀerent techniques, such
as emulsion polymerization and nanoprecipitation.1 Among all
the types of NPs produced in literature, those obtained via
direct self-assembly in water of amphiphilic species, such as
block copolymers, have the advantage to eliminate the need of
toxic surfactants and to load the therapeutic directly during the
NP formation. In this case the NP core is formed by the lipo-
philic part of the forming block copolymer and serves as a depot
for hydrophobic compounds. For an eﬀective delivery system,
the lipophilic core forming chains should be able to load theChemical Engineering “Giulio Natta”,
20131 Milano, Italy. E-mail: umberto.
Ricerche Farmacologiche Mario Negri, Via
(ESI) available: Characterization of the
of the diblock copolymers. See DOI:
hemistry 2017highest amount possible of the therapeutic and to degrade in
biocompatible, non-toxic and easily excretable compounds.
Among the species adopted in the literature to full these
functions, poly(lactide) (PLA) and poly(3-caprolactone) (PCL)
chains have been chosen as “golden standards”.
On the other hand, the hydrophilic part of the block copol-
ymer forms the NP shell and provides colloidal stability and
protects the loaded drug against protein adsorption and opso-
nisation. Among the hydrophilic species adopted for the stabi-
lization of these carriers, poly(N-(2-hydroxypropyl)
methacrylamide) (poly(HPMA)) is an attractive alternative to the
polyethylene glycol (PEG) chains, by far the most adopted for
biomedical applications. Besides its biocompatibility and its
non-immunogenicity, an advantage of poly(HPMA) over PEG is
its secondary alcohol functionality, which allows multiple tar-
geting molecules to be conjugated to the same polymer chain.
In addition, poly(HPMA) has been proved to not generate any
accelerated blood clearance and allergic reaction compared to
the PEG.2–4
The synthesis of well-dened amphiphilic block copolymers
was made possible by the advent of living polymerization
techniques, such as the reversible addition–fragmentation
chain transfer (RAFT) polymerization that allows the ne tuningRSC Adv., 2017, 7, 50981–50992 | 50981
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View Article Onlineof the polymer architecture and, in turn, of the NP properties.5,6
Besides, the ring opening polymerization (ROP) has allowed to
produce PCL and PLA based biodegradable macromonomers
with diﬀerent lengths exploiting 2-hydroxyethyl methacrylate
(HEMA) as initiator, a monomer that possesses a primary
alcohol functionality.7,8 Then, the combination of RAFT and
ROP provides an eﬀective technique to obtain well dened
block copolymers able to self-assemble into NPs with diﬀerent
size. However, the so called “macromonomer method” for the
production of oligoester-based macromonomers is not able to
work properly in some conditions and the “inversion” of the
method is sometimes necessary. It consists in the synthesis of
the oligoester via ROP using a primary alcohol as initiator fol-
lowed by the functionalization of the chain end with a double
bond. As an example, in the work of Ferrari et al., where
a macromonomer based on the low reactive decanolide and
dodecanolide was produced, the polyester chain has been
produced rst and then conjugated with a monomer that bears
a carboxylic acid via a N,N0-dicyclohexylcarbodiimide (DCC)-
mediated esterication.9 In fact, these lactones require
a strong base as catalyst that is also able to destroy the double
bond in the direct method. The inversion of the macro-
monomer method is also a good strategy for the functionali-
zation of the nal side chain. As an example, when a xed
positive charge is wanted, it is not possible to directly use
a quaternary ammonium salt that bears a hydroxyl group (i.e.
choline chloride) as initiator in the ROP due to its insolubility in
the lactone and in the common organic solvents. For this
reason, in the paper of Rooney et al., a tertiary amine bearing an
alcohol functionality was adopted as the initiator in the ROP of
3-caprolactone and the double bond was then added to the
polyester chain by the reaction with methacryloyl chloride. In
the end, the tertiary amine was transformed into the corre-
sponding quaternary ammonium salt via reaction with methyl
iodide.10,11 The macromonomer method fails also when HPMA
is used as the initiator in the ROP of cyclic esters. This is due to
its very low reactivity as a consequence of being a secondary
alcohol. In the literature, a direct synthesis of a PLA based
macromonomer exploiting the HPMA as the initiator was
proposed.12 From a close inspection of the product obtained in
that case, it is possible to note a low HPMA conversion that led
to a poor control over the macromonomer structure, despite
narrowly dispersed polymers could be obtained.
Here we report for the rst time the synthesis of a well-
dened HPMA-functionalized oligoester via the inversion of
the macromonomer method. In particular, the macromonomer
is obtained in three steps: (i) the ROP of caprolactone (CL) with
benzyl alcohol (BA) as initiator; (ii) the acylation of the –OH
bearing PCL chain with succinic anhydride and (iii) the further
DCC-mediated esterication with HPMA. In particular, BA has
been chosen as the co-catalyst in the ROP since it is a reactive
primary alcohol with a high boiling point and because it is less
toxic than the alkyl alcohols that are commonly adopted (e.g.
dodecanol).13 The resulting macromonomer (hereinaer
HPMA-CL5, where 5 is the number of caprolactone units added
to the chain) was subsequently used to obtain biodegradable
polymeric nanoparticles that are suitable for the drug delivery50982 | RSC Adv., 2017, 7, 50981–50992of poorly water soluble therapeutics. In order to produce these
nanoparticles, a two-step sequential RAFT polymerization was
adopted. In the rst step, a poly(HPMA) water soluble block was
obtained to provide steric stabilization to the NPs. Then, the
obtained macro RAFT agent was chain extended with the novel
lipophilic macromonomer containing HPMA. The obtained
amphiphilic diblock copolymer is able to self-assemble in water
via a simplied nanoprecipitation method with a rudimental
apparatus, thus allowing the NP production shortly before the
injection. Furthermore, the copolymer is designed to progres-
sively degrade via the hydrolysis of the ester bonds in the PCL
side chains. Thementioned NP degradation behaviour has been
studied and resulted into the complete disappearance of the
carriers leaving only the water soluble poly(HPMA) backbone,
which is expected to be easily excreted by the kidneys due to its
low molecular weight.1 The NP cytotoxicity and the ability to
load trabectedin, a hydrophobic anticancer compound, have
been nally assessed.2. Materials and methods
2.1 Materials
Succinic anhydride ($99%), 4-(dimethylamino)pyridine (DMAP,
$99%), methacryloyl chloride ($97%), DL-1-amino-2-propanol
($98%), sodium carbonate ($99%), N,N0-dicyclohexylcarbo-
diimide (DCC, 99%), tin(II)2-ethylhexanoate (Sn(Oct)2, 98%), 3-
caprolactone (CL, 97%), benzyl alcohol (BA, $99%), anhydrous
sodium sulphate (Na2SO4, $99%), 4,40-azobis(4-cyanovaleric acid)
(ACVA,$98%) and 4-cyano-4-(phenylcarbonothioylthio) pentanoic
acid (CPA,$97%)were all purchased from Sigma Aldrich and used
as received except when specically noted. The phosphate buﬀered
saline solution (PBS, Biowest) and the cell medium, that was
composed of high glucose DMEM/F12 (Biowest, Nuaill´e, France)
and supplemented with 10% fetal bovine serum (Lonza, Basel,
Switzerland) were used as received. All the solvents used were of
analytical-grade purity and were purchased from Sigma Aldrich.2.2 HPMA synthesis
The HPMA was synthesized following a procedure reported in
literature.14 Briey, 25.22 g (238 mmol) of sodium carbonate
were suspended in 56 mL of anhydrous dichloromethane
(DCM). The temperature was kept at 10 C using a brine\ice
mixture and 16.25 g (216 mmol) of DL-1-amino-2-propanol were
added. Finally, 22.60 g (216 mmol, 1 : 1 with respect to DL-1-
amino-2-propanol) of freshly distilled methacryloyl chloride
were dissolved in 22 mL of DCM and the solution was fed to the
reaction ask kept at 10 C in 45 minutes under vigorous
stirring. The mixture was le to equilibrate to room tempera-
ture and allowed to react for further 30 minutes. Then, the
product was recovered by ltration, dried twice with anhydrous
Na2SO4, concentrated under vacuum and le to crystallize at
20 C overnight. Finally it was washed with cold DCM and
recrystallized from acetone. The purity of the product was
assessed via proton Nuclear Magnetic Resonance (1H NMR) in
deuterium oxide (D2O) using a Bruker 400 MHz spectrometer
and the yield was up to 65%.This journal is © The Royal Society of Chemistry 2017
Scheme 1 Synthesis of hydrophilic poly(HPMA) obtained via RAFT polymerization.
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View Article Online2.3 HPMA RAFT polymerization
A hydrophilic poly(HPMA) with an average degree of polymeri-
zation (DP) equal to 70 was synthesized via RAFT polymeriza-
tion in a mixture of acetic buﬀer/ethanol (Scheme 1).
Specically, 1.1 g of HPMA (7.69 mmol), 31 mg of CPA
(0.11 mmol, HPMA/CPA mole ratio equal to 70), 10.3 mg of
ACVA (0.04 mmol, CPA/ACVA mole ratio equal to 3) were dis-
solved in 3 g of ethanol and 7 g of acetic buﬀer and poured in
a septa-sealed round bottom ask. Themixture was purged with
nitrogen for 30 minutes and heated to 70 C under stirring. The
polymerization was le to proceed for 24 hours, the solvent
evaporated under vacuum and the polymer precipitated three
times in tetrahydrofuran (THF). Aliquots of the reactive mixture
were taken at diﬀerent times, dried under a nitrogen ow and
analyzed via 1H NMR (in D2O) and gel permeation chromatog-
raphy (GPC) to evaluate the monomer conversion and the MW
distributions over time. GPC analysis was performed at 35 CScheme 2 Synthesis protocol to obtain the HPMA-based lipophilic macr
the product using succinic anhydride and (c) DCC-mediated esteriﬁcatio
This journal is © The Royal Society of Chemistry 2017using a mixture of 20/80% acetonitrile (ACN)/0.05 M Na2SO4 as
eluent and at a ow rate of 0.5 mLmin1. The instrument (Jasco
apparatus) comprises a diﬀerential refractive index (RI)
detector, three Suprema columns (Polymer Standards Service,
particle size 10 mm, pore sizes of 100, 1000, and 3000 A˚) and
a pre-column. A universal calibration was applied based on
polyethylene glycol (PEG) standards.
2.4 Synthesis of HPMA-PCL5
As schematically reported in Scheme 2, the lipophilic HPMA-
based macromonomer was synthesized by a three-step proce-
dure: (i) ROP of CL with BA as the initiator and tin octoate as the
catalyst, (ii) subsequent acylation of the product using succinic
anhydride and (iii) DCC-mediated esterication of the obtained
oligo(caprolactone) bearing a nal carboxyl group with HPMA.
In the rst step (Scheme 2a), the ring opening polymerization
was conducted with a CL/BA mole ratio and BA/Sn(Oct)2 ratio
equal to 5 and 1/200, respectively. 10.55 g of CL (92.4 mmol) andomonomer: (a) BA initiated ROP of the 3-caprolactone; (b) acylation of
n of the carboxylic acid terminated oligo(caprolactone) with the HPMA.
RSC Adv., 2017, 7, 50981–50992 | 50983
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View Article Online37 mg of Na2SO4, added to remove water from the system, were
heated to 130 C in a septa-sealed ask under stirring. 2 g (18.5
mmol) of BA were mixed with 37 mg (9.1  105 mol) of tin
octoate and injected in the pre-heated CL containing ask. The
polymerization was allowed to proceed for 2.5 hours.
The subsequent acylation (Scheme 2b) was obtained in bulk
conditions by adding 1.2 mol equivalents of succinic anhydride
to the obtained BA-CL5. Briey, 2.22 g (22.2 mmol) of succinic
anhydride were poured directly into the ask of the previously
synthesized oligo(caprolactone) and the mixture was heated to
90 C and le to react overnight. The nal product was puried
by dissolution in THF and further precipitation in water.
In the third step (Scheme 2c), HPMA-CL5 was obtained via
DCC-mediated esterication between the previously synthe-
sized BA-CL5Q and a 20% molar excess of HPMA, exploiting the
DMAP as the catalyst. More in detail, 8.03 g (12 mmol) of BA-
CL5Q and 2.09 g (15 mmol) of HPMA were dissolved in 40 mL
of anhydrous DCM. The solution was poured in a 100 mL septa-
sealed ask kept at 0 C in a water/ice bath. Finally, 270 mg (2.2
mmol) of DMAP and 2.85 g (14 mmol) of DCC dissolved in
40 mL of anhydrous DCM were fed over a period of 1 h into
ask. The reaction was le to equilibrate at room temperature
and to react for additional 24 hours. Then the mixture was
ltered to remove the white precipitate formed as the co-
product of the esterication and the solvent evaporated under
vacuum. The dry product was dissolved in THF and precipitated
in a large excess of water. The obtained macromonomer was
nally recovered as a white waxy solid.
For each intermediate step, an aliquot of the sample was
withdrawn and analyzed via 1H NMR (in CDCl3), GPC and
matrix-assisted laser desorption/ionization – time of ight
(MALDI-TOF). In this case, GPC analysis was performed at 35 C
using THF as the eluent and a ow rate of 0.5 mL min1. The
instrument (Jasco apparatus) comprises a diﬀerential refractiveScheme 3 Synthesis of the HPMA-based amphiphilic block copolymers
50984 | RSC Adv., 2017, 7, 50981–50992index (RI) detector, three PL gel columns (Polymer laboratories
Ltd., UK; two columns had pore sizes of the mixed-C type and
one was an oligopore; 300 mm length and 7.5 mm ID) and a pre-
column. A universal calibration was applied based on poly-
styrene (PS) standards. MALDI-TOF spectra were recorded using
an Ultraex II TOF Bruker spectrometer (Bremen, Germany)
using 2-[(2E)-3-(4-tert-butylphenyl)-2-methylprop-2-enylidene]-
malononitrile (DCTB) as the matrix material. The samples
that were co-crystallized with the matrix on the probe were
ionized using a Smart Beam laser pulse (337 nm) and acceler-
ated at 25 kV with a time-delayed extraction before entering the
time-of-ight mass spectrometer. The matrix and sample were
separately dissolved in DCM and mixed in a 10 : 1 matrix to
sample ratio. To produce the specic adducts, sodium ions were
added (1% sodium acetate in methanol). Approximately 1 mL of
the mixture of matrix and sample was spread on the MALDI-
TOF MS probe and air-dried. All the spectra were obtained in
positive reection mode, and the external calibration was per-
formed by using the peptide calibration standard II (700–3200
Da) from Care (Bruker, Switzerland).2.5 Synthesis of block copolymers
The amphiphilic block copolymers constituted by a uniform
poly(HPMA) backbone were synthesized via the RAFT polymer-
ization in ethanol of the HPMA-CL5 lipophilic macromonomer
in the presence of the previously synthesized poly(HPMA), used
as the macro-RAFT agent. Four diﬀerent copolymers were
synthesized with a nal DP of the hydrophobic block equal to 2,
5, 10 and 20. The tuning of the DP was obtained by simply
regulating the initial molar ratio between the HPMA-CL5 mac-
romonomer and the macro-RAFT agent. The nomenclature
adopted is composed by the hydrophilic block DP followed by
the lipophilic block DP (i.e. 702 is applied to the polymervia RAFT polymerization.
This journal is © The Royal Society of Chemistry 2017
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View Article Onlinecomposed by 70 HPMA units and 2 HPMA-CL5 units). The
synthesis procedure is represented in Scheme 3.
In a typical reaction, for the synthesis of 702 (70 units of
HPMA and 2 units of HPMA-CL5), 0.647 g of poly(HPMA) and
0.141 g of HPMA-CL5 (HPMA-CL5/poly(HPMA) mole ratio equal
to 2) were dissolved in 4 mL of ethanol. The solution was
transferred in a septum-sealed ask and purged with nitrogen
for 30 minutes. The solution was then heated to 70 C and
10 mg of ACVA dissolved in 1 mL of ethanol was fed under
stirring. The reaction was le to occur for 24 h, aer which the
same amount of ACVA was added and the reaction went on for
additional 24 h. The solvent was then evaporated under vacuum
and the polymer puried by precipitation in a large excess of
diethyl ether. Aer drying under a ow of nitrogen, the polymer
was collected as a pink powder and characterized via 1H NMR in
deuterated dimethylsulfoxide (DMSO-d6).
2.6 NP formation via a simplied nanoprecipitation method
HPMA-based NPs have been obtained following a simple
nanoprecipitation process without the use of any mixing
devices that are commonly adopted to obtain strongly turbulent
conditions between the organic and the aqueous phases. In this
case, diﬀerent amounts of the bulk block copolymers were
dissolved in 0.3 g of DMSO. This organic solution was then
added dropwise to 3 mL of PBS under vigorous agitation. In
order to investigate the NP behaviour, diﬀerent polymer
concentrations in DMSO were tested. In particular, the amount
of DMSO was kept constant (0.3 g) and diﬀerent quantities of
the block copolymer were used: 75 mg, 52 mg, 33 mg, 15 mg,
10 mg and 5 mg to achieve a nal polymer concentration of
20%, 15%, 10%, 5%, 3.5% and 1.5% w/w respectively. These
diﬀerent concentrations were tested for all of the four block
copolymers. The NP size was then analyzed via Dynamic Light
Scattering (DLS, Malvern Zetasizer Nano ZS) at a scattering
angle of 173. The particle size distribution (PSD) is an average
of three independent measurements. Transmission Electron
Microscopy (TEM) images of the synthesized NPs were obtained
using a FEI Morgagni 268 instrument, operated at 120 kV,
equipped with an Orius SC1000 CCD camera.
2.7 NP degradation
The NP degradability was investigated in PBS at 37 C for several
days. Briey, the NP suspensions in PBS, obtained using a 10%
w/w polymer concentration in the organic phase, were stored in
a thermostated oven at 37 C and periodically analyzed via DLS
in order to evaluate the changes in their average size, poly-
dispersity index (PDI) and intensity of the scattered light (count
rate). DLS measurements were performed 1, 4, 7, 10, 14, 17, 22,
25 and 30 days aer the synthesis.
2.8 NP cytotoxicity
The 702 and 705 NP cytotoxicity was studied in vitro in the case
of the triple negative breast (TNB) cancer MDA-MB-231 cell line
(American Type Culture Collection, Manassas, VA). The cells
were seeded in six-well plates (Costar) at the concentration of
20 000 cells per mL. 24 h aer the seeding, the cells wereThis journal is © The Royal Society of Chemistry 2017incubated with 0.9, 0.4 and 0.02 mg mL1 of NPs. Aer 48 h of
exposure, the cells were detached using 0.5 mL of trypsin, re-
suspended in 2 mL of PBS and counted using a Coulter
Counter ZM (Coulter Electronics, UK). The procedure was
applied three times for each concentration and the average
number of viable cells was considered and expressed as
a percentage of the viable untreated cells (control) at the same
time.2.9 Trabectedin loading and release test
The loading of trabectedin was performed in the same step of
the NP production. Briey, 10 mg of the block copolymer (702
and 705) and trabectedin (75 mg) were dissolved in 100 mg of
DMSO. Aer complete dissolution, the nanoprecipitation
method was applied with 3 mL of PBS. The NP suspension was
dialyzed against 200 mL of PBS for 24 h and the release was
evaluated by withdrawing aliquots of the formulation in the
dialysis cassette (Slide-A-Lyzer dialysis cassette, Thermo Scien-
tic MWCO ¼ 3.5 kDa) aer 0, 0.25, 0.5, 1, 4, 24 h. The PBS was
periodically changed in order to preserve the sink conditions.
Each sample was then analyzed via liquid chromatography –
tandem mass spectrometry (LC-MS/MS) as previously
described.15,16 Briey, 0.1 mL of the NP suspension were spiked
with 100 ng of deuterated trabectedin as internal standard and
50 mL (NH4)2SO4 : H2O ¼ 1 : 3. Samples were extracted with
0.4 mL of CH3OH, HCl 0.1 M. Aer shaking for 10 s, samples
were centrifuged at 13 000 rpm for 10 min. The organic phase
was separated and dried under nitrogen, and the residues were
dissolved in 250 mL of mobile phase constituted by a 1 : 1
ammonium acetate buﬀer (10 mM pH 6.8): CH3OH solution.
Two mL of the reconstitute samples were injected in the LC-MS/
MS system. The apparatus comprises an Accucore C18 column.
Control NPs without drug were used to prepare the calibration
curve by the addition of trabectedin in the range 1–40 mg mL1.3. Results and discussion
3.1 Synthesis of poly(HPMA)-based macro RAFT agent
The HPMA monomer was synthesized according to the litera-
ture.12,14,17 To assess the purity of the produced monomer, 1H
NMR analysis in D2O was performed and the obtained spectrum
is reported in Fig. S1a.† The spectrum conrms the proper
structure of the monomer and its purity aer the workup
protocol. The synthesized monomer was then polymerized via
RAFT polymerization in order to obtain the hydrophilic
macromolecular chain transfer agent (macro-CTA) employed in
the synthesis of amphiphilic diblock copolymers and as steric
stabilizer for the nal NPs. The polymerization was carried out
in an acetic buﬀer (pH ¼ 5)/ethanol mixture with a low mono-
mer concentration since it is well known that the propagation
kinetic constant (kp) of hydrophilic monomers is higher in water
due to its benecial eﬀect on the transition state of the propa-
gation step and increases as the monomer concentration
decreases.18,19 On the other hand, ethanol is necessary to
dissolve the CPA. The DP of the polymer can be tuned by
controlling the monomer/CPA mole ratio. In this case a DPRSC Adv., 2017, 7, 50981–50992 | 50985
Fig. 1 Direct ROP of 3-caprolactone using HPMA as the co-catalyst.
Conversion over time for: HPMA (ﬁlled squares) and CL (open squares)
using a HPMA/Sn(Oct)2 mole ratio of 100; HPMA (ﬁlled circle) and CL
(open circle) in the case of a HPMA/Sn(Oct)2 mole ratio equal to 50.
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View Article Onlineequal to 70 was targeted. The 1H NMR spectrum of the poly(-
HPMA) is reported in Fig. S1b.† By evaluating the area of the
vinyl signal and that of the signal E, it is possible to assess that
a 97% monomer conversion is reached during the polymeriza-
tion. Further from the NMR spectrum it is possible to evaluate
the average DP according to eqn (1).
DPave ¼ areaEareaA þ areaB þ areaC
5
(1)
Being A, B and C the signals related to the benzyl chain-end
group. From eqn (1) it is possible to demonstrate that the
synthesized poly(HPMA) is constituted by an average DP of 75,
that is in good accordance with the target (i.e. DP ¼ 70). To
demonstrate the living nature of the reaction, the kinetic of the
process was evaluated by measuring the monomer conversion
(via 1H NMR) and the molecular weight of the polymer over
time. From Fig. S2a† it is possible to note that a logarithmic
trend of the conversion versus time is obtained and a monomer
conversion up to 80% is achieved within the rst 24 hours of
reaction. However, an initial inhibition time of 1.5 h is experi-
enced. As reported in literature, this is a common feature of the
RAFT polymerization, especially when the DP is low.20 Analyzing
then themolecular weight provided by the GPC, a linear trend is
obtained versus the conversion. This conrms the living char-
acter of the RAFT polymerization, for which a linear dependency
of the molecular weight from the conversion is expected
according to eqn (2).
Mn ¼ ½M0c½CPA0
Mw M þMw CPA (2)
where c is the monomer conversion, [M]0 and [CPA]0 are the
initial molar concentrations of the monomer and the RAFT
agent, Mw M and Mw CPA are the molecular weights of the
monomer and the RAFT agent, respectively.3.2 Synthesis of HPMA-CL5 hydrophobic macromonomer
The traditional way to synthesize oligoester-based lipophilic
macromonomers is the direct ROP of a cyclic ester (i.e. 3-cap-
rolactone, lactide, glycolide) exploiting a vinyl group bearing
alcohol as the co-catalyst.7,21–26 Then, a direct synthesis
exploiting HPMA as the co-catalyst in the ROP of the 3-capro-
lactone was tested using diﬀerent HPMA/Sn(Oct)2 mole ratios
and a reaction temperature of 130 C. The conversion of both
the HPMA and the caprolactone over time, evaluated via 1H
NMR, is reported in Fig. 1.
It is possible to observe that CL is very reactive during the
ROP, and its conversion reaches values higher than 90% aer
4 h for both the HPMA/Sn(Oct)2 mole ratios that were tested.
However, the situation is diﬀerent for the HPMA. In this case,
the maximum conversion that can be obtained aer 4 h is just
of 60%. This very low HPMA conversion can be explained by
considering the lower reactivity of a secondary alcohol
compared to that of a primary alcohol like 2-hydroxyethyl
methacrylate that is commonly used in the ROP of cyclic
esters.7,21,23,26–30 This low HPMA conversion inevitably prevents50986 | RSC Adv., 2017, 7, 50981–50992the control of the molecular weight of the produced macro-
monomer. In fact, a DP (estimated via 1H NMR. Fig. S3 in the
ESI section†) equal to 9 is obtained instead of the target value of
5. For this reason, in order to obtain a macromonomer with the
desired molecular weight and number of CL units, the inversion
of the macromonomer synthesis method is required and
a three-step process is proposed in this work. The rst step is
the ROP of the CL exploiting the benzyl alcohol that is a very
reactive primary alcohol, as the co-catalyst, in order to produce
a well dened oligo (CL) with a target DP equal to 5. The 1H
NMR spectrum of this rst intermediate is reported in Fig. 2a.
In this case, the ROP reached a 94% conversion for the BA
just aer 3 h. The average number of CL units added to the
oligomer can be evaluated according to eqn (3).
DP ¼ areaF
areaG
þ 1 (3)
From Fig. 2a it is possible to calculate an average DP value of
4.9, which is close to the target. The second step in the synthesis
of the HPMA-CL5 macromonomer is the acylation of the
produced BACL5 using succinic anhydride in order to obtain
a carboxylic acid-terminated molecule active in the esterica-
tion reaction. The acylation was conducted in bulk conditions at
90 C. At this temperature, the succinic anhydride can be dis-
solved in the liquid BACL5. The 1H NMR spectrum of the
produced BACL5Q is reported in Fig. 2b. From this spectrum,
the disappearance of the peak at 3.7 ppm (G in Fig. 2a) conrms
the complete functionalization of the BACL5. Further, no
residual succinic anhydride is detected aer the purication
protocol. The synthesized BACL5Q was nally reacted with the
HPMA in a DCC-mediated esterication reaction using DMAP
as the catalyst. This led to the HPMA-CL5 macromonomer,
whose 1H NMR spectrum is reported in Fig. 2c. In this case, the
shi of the H peak to 5.15 ppm compared to the original
chemical shi of 4 ppm in the HPMA NMR spectrum (peak D inThis journal is © The Royal Society of Chemistry 2017
Fig. 2 1H NMR spectra, recorded in CDCl3, for: (a) BACL5, (b) BACL5Q and (c) HPMA-CL5.
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View Article OnlineFig. S1a†) conrms the functionalization of the HPMA and the
success of the esterication reaction. The molecular weight
distribution of the nal macromonomer was also studied via
both MALDI-TOF and GPC analysis (Fig. S5 and S6 in the ESI
section, respectively†) and an average value of 1179 g mol1
with a polydispersity equal to 1.14 was obtained, in agreement
with the theoretical values.3.3 Synthesis of block copolymers
The poly(HPMA) macro-CTA was chain-extended with the
synthesized HPMA-CL5 macromonomer via solution RAFT poly-
merization conducted in ethanol with a [macro-CTA]/[ACVA] mole
ratio equal to 3. Diﬀerent DPs for the lipophilic block were tar-
geted (i.e. 2, 5, 10 and 20), in order to evaluate the impact of theTable 1 Lipophilic monomer conversion after 24 h and 48 h with an
extra ACVA addition after 24 h and ﬁnal theoretical molecular weight
based on the monomer conversion provided by the 1H NMR for the
four diblock copolymers synthesized
Block copolymer c24 h [%] c48 h [%] Mn [Da]
702 46.23 88.02 11 300
705 54.13 88.62 14 400
7010 43.66 80.62 18 400
7020 34.6 80.50 27 600
This journal is © The Royal Society of Chemistry 2017HPMA-CL5 macromonomer over the self-assembly behaviour of
the block copolymers, the NP size and their performance as drug
delivery vectors. The monomer conversion during the process was
evaluated via 1H NMR (Fig. S7 in the ESI section†) and summa-
rized, for the four diblock copolymers, in Table 1.
In particular, the monomer conversion is quite low aer the
rst 24 h at 70 C, never reaching values higher than 54%.
However, a considerable improvement is achieved by a succes-
sive initiator addition and further 24 h at 70 C. In this case the
monomer conversion signicantly increases reaching up the
88% aer an overall 48 h reaction. Besides, this further initiator
addition has no detrimental eﬀects on the polymer structure, as
conrmed by the NMR spectrum reported in Fig. S7.†3.4 Nanoparticle synthesis via a simplied
nanoprecipitation method and degradation study
The synthesized block copolymers were assembled in mono-
disperse polymer NPs via a nanoprecipitation method that
greatly simplies the instrumental apparatus usually adopted
for this purpose. The polymer is dissolved in few microliters of
DMSO as the organic solvent and the nanoprecipitation occurs
via the dropwise addition of the organic phase to PBS kept
under vigorous agitation on a magnetic stirrer. This very simple
method avoids the use of sonication, pumps andmixing devices
that are commonly employed to obtain the eﬃcient polymer
self-assembly.30,31 In this way, the NP synthesis can be le to theRSC Adv., 2017, 7, 50981–50992 | 50987
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View Article Onlineend-user, thus avoiding intermediate steps like the lyophiliza-
tion and dialysis. The polymer concentration in the organic
phase can be in fact increased up to 20% w/w without a signif-
icant impact over the nal PSD, so that a minimal amount of
organic solvent is required to formulate the polymer. The PSD of
the diﬀerent block copolymers using this method and the
inuence of the polymer concentration in DMSO on the average
NP size are reported in Fig. 3.
From Fig. 3a it is possible to observe that monodisperse
polymer NPs can be obtained with the simplied nano-
precipitation method even at a high polymer concentration in
the organic phase (i.e. 15%w/w). This is a very important feature
since it allows using only small amount of DMSO, that is well
tolerated and poorly cytotoxic at concentrations lower than 10%
w/w in the infused solution.32–35 In addition, the formulation is
obtained using only readily available instruments, without the
necessity of any particular equipment, thus paving the way to
the NP production directly by the end-user and few moments
before their injection, thus solving important concerns that are
usually associated to colloidal dispersions, such as storage and
transport.36–39 The TEM picture reported in Fig. 3b for the 702
NPs as an example further conrms the data obtained by the
DLS analysis, proving that monodisperse, round shaped NPs
can be obtained.
A key point, when producing ready-to-use NPs is the mini-
mization of the organic solvent used to dissolve the polymer.
However, this inevitably leads to an increase in the viscosity ofFig. 3 (a) PSD obtained from the DLS analysis for the 702 (green dotted
dashed line) diblock copolymers obtained following their nanoprecipitati
DMSO of 15% w/w. (b) TEM picture of the NPs obtained from the 702 d
(scale bar 200 nm). (c) Inﬂuence of the polymer concentration in DMSO o
( ), 705 ( ), 7010 ( ) and 7020 ( ) diblock copolymers.
50988 | RSC Adv., 2017, 7, 50981–50992the organic phase, thus hardening the polymer self-assembly
during the nanoprecipitation that is generally conducted
under dilute conditions.40–42 Since high polymer concentration
in the organic phase could have a detrimental eﬀect on the
quality of the nal NPs, its eﬀect over both the NP size and PDI
has been investigated. In particular, from Fig. 3c it is possible to
observe that by increasing the polymer concentration in DMSO
the NP size initially increases for all the synthesized copoly-
mers. However, for concentrations higher than 5%w/w, a sort of
plateau is reached, with the size that only slightly uctuates
around an average value (i.e. 100 nm for the 702, 180 nm for the
705, 168 nm for the 7010 and 176 nm for the 7020). On the other
hand, the PDI remains almost constant and around 0.2 over the
whole concentration range, as it can be noticed from Fig. 3d. It
was nally observed that with a concentration higher than 20%
w/w, the polymer is only hardly soluble in DMSO.
In conclusion, a poly(HPMA70-b-HPMA-CL5n) biodegradable
diblock copolymer constituted by a homogeneous HPMA
backbone could be successfully assembled in monodisperse,
round shaped NPs using a simplied nanoprecipitation
method. This allows producing ready-to-use NPs due to the use
of a very little amount of DMSO and rudimental equipment.
The NPs synthesized from the HPMA-based lipophilic mac-
romonomer are composed of short oligo(caprolactone) side
chains that can undergo hydrolytic degradation in water. The
possibility for a nanovector specically designed for intrave-
nous administration to degrade leaving no traces is a mainline), 705 (blue dash-dotted line), 7010 (black solid line) and 7020 (red
on in PBS using the simpliﬁed method with a polymer concentration in
iblock copolymer with a polymer concentration in DMSO of 10% w/w
ver the NP intensity-averaged size and (d) over the NP PDI for the 702
This journal is © The Royal Society of Chemistry 2017
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View Article Onlineconcern to avoid polymer accumulation into the bloodstream,
as already stressed in the literature.1,8,43 Then, the degradation
behaviour of the NPs obtained from the four diﬀerent diblock
copolymers has been studied at 37 C using PBS (pH ¼ 7.4) as
the medium. This is a biologically relevant medium since it is
commonly used for intravenous injections. The evolution of the
NP size as obtained via DLS over time aer the NP incubation at
37 C is reported in Fig. 4a.
From a close inspection, it is possible to observe that the size
does not change signicantly over 30 days for the copolymers
705, 710 and 7020. This suggests the ability of the poly(HPMA)
block to provide colloidal stability to the produced NPs, avoid-
ing their aggregation, over a signicant period of time. An
exception to this trend is represented by the 702 NPs. In this
case their average size abruptly increases aer 4 days. It is not
surprising that this behaviour is recorded for the copolymer
with the lowest molecular weight for its lipophilic block. The
degradation of the few oligo(caprolactone) chains leads to an
increase in the NP hydrophilicity that, in turn, causes them to
signicantly swell in water. Aer having reached a maximum
size aer 10 days the NPs cannot be detected any longer viaDLS.
In fact, the complete degradation of the lipophilic monomer
leaves a highly hydrophilic poly(HPMA) backbone that is
molecularly dissolved in PBS. From Fig. 4b it is clear that the
PDI follows a trend that is similar to the NP size, being almostFig. 4 Evolution of (a) intensity-averaged size, (b) PDI and (c) relative scat
705 ( ), 7010 ( ) and 7020 ( ) NPs in PBS incubated at 37 C over a mon
days (red dashed line) and after 10 days (blue dotted line) at 37 C.
This journal is © The Royal Society of Chemistry 2017constant for the 705, 7010 and 7020 NPs thus providing
a further proof of the colloidal stability provided by the poly(-
HPMA) block. Again, the PDI signicantly increases for the 702
NPs starting from the fourth day, in correspondence with the
size increase. An important parameter to be considered when
studying NP degradation is the relative scattering intensity,
which is directly related to the NP size and concentration.44,45
The trend of this parameter over time is reported in Fig. 4c. For
the 702 NPs, the relative scattering intensity rapidly decreases,
reaching the 35% of its original value aer 10 days. Since the NP
size is increasing during this period, this signicant reduction
in the scattering intensity suggests that the NPs are dissolving
and that the degradation is almost complete aer 10 days. The
degradation is much slower for the 705, 7010 and 7020 NPs, for
which the relative scattering intensity reaches the 56%, 65%
and 88% of the original value aer 30 days, respectively. This
progressive reduction in the degradation rate as the lipophilic
block DP increases is not surprising. In fact, the higher the
lipophilic block DP, the lower the hydration that is expected for
the core forming block. This reduces the local water concen-
tration into the core and then slows down the kinetic of the
hydrolysis reactions, as already proposed in the literature.23,46–48
Finally, the evolution of the PSD for the 702 NPs is reported in
Fig. 4d. Here it is possible to observe that shortly upon the
synthesis, a unimodal PSD is obtained. However, aer 7 days,tering intensity referred to the initial time t¼ 0 over time for the 702 ( ),
th. (d) PSDs for the 702 NPs after the synthesis (black solid line), after 7
RSC Adv., 2017, 7, 50981–50992 | 50989
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View Article Onlinea second NP population centered at 260 nm is formed, thus
suggesting the NP swelling as a consequence of the degradation
and the progressively increasing hydrophilic character of the
diblock copolymer. The presence of a second peak can be
explained considering that the degradation mechanism is not
homogeneous.8 Finally, aer 10 days the presence of residual,
low size micelles is detected by the DLS before the complete
dissolution of the copolymer. This degradation mechanism was
already observed and described in the case of NPs obtained via
emulsion polymerization from PCL-based macro-
monomers.8,23,49 However, in this work, the synthesis of the
lipophilic part of the block copolymer via a combination of ROP
and RAFT polymerization allows to nely tune the NP degra-
dation time in order to obtain drug carriers with an optimized
half-life. The progressive release of the oligo(caprolactone) side
chains is designed to leave the water soluble, low molecular
weight poly(HPMA). The combination of complete solubility
and low MW makes the degradation residue easily excreted by
the kidneys, which is a key factor in avoiding the risk of polymer
accumulation.1Fig. 5 (a) Cell viability, expressed as the percentage of viable cells with
respect to the control, after 48 h exposure with 702 (grey bars) and 705
(white bars) NPs at diﬀerent NP concentration in the medium. (b)
Evolution of the amount of the released trabectedin from 702 ( ) and
705 ( ) NPs.3.5 Cytotoxicity and trabectedin release
To further prove the suitability of the produced NPs as nano-
vectors aimed at parenteral administration, their in vitro cyto-
toxicity was evaluated in the case of the TNB cancer MDA-MB-
231 cells aer exposing them to diﬀerent concentrations of
NP suspension for 48 h. The cell viability expressed as
a percentage of the control is reported in Fig. 5a in the case of
702 and 705 NPs.
It can be noticed that both 702 and 705 proved to be highly
biocompatible, even at the highest concentration in the
medium. This is not surprising considered that poly(HPMA) is
known to be non cytotoxic and that the biocompatibility of
polyesters like PLA and PCL has been already demonstrated
elsewhere.50–53 However, a slightly decrease in the cell viability
(i.e. 88%) is recorded for cells exposed at 0.9 mgmL1 of 705 NP
suspension. This could be due to the sensitivity of the polymer
towards hydrolysis of the dithioester of the RAFT agent.43,54
Finally, the ability of the produced amphiphilic NPs to
encapsulate and mediate the release of a hydrophobic, anti-
tumour drug was studied in the case of trabectedin. The
loading eﬃciency, expressed as the amount of drug entrapped
into the NP core compared to that loaded in the process, was
equal to 75% and 90% for the 702 and the 705 NPs, respectively
(i.e. 5.6 mg and 6.8 mg of trabectedin loaded per mg of polymer).
These very high values can be explained considering the
simultaneous NP formation and drug loading obtained with the
proposed nanoprecipitation method, which leads to a higher
loading eﬃciency compared to a post-synthesis loading
process.49,55 Further, the higher lipophilic block MW in the case
of the 705 NPs is responsible for a higher loading eﬃciency
compared to the 702 NPs. Once the trabectedin was loaded into
the NP core, its release was studied via LC-MS/MS and the
results are reported in Fig. 5b. It can be observed that aer
a 30% initial burst release accomplished within 2 h, the drug
was sustainedly released for over 24 h. The trabectedin amount50990 | RSC Adv., 2017, 7, 50981–50992released aer this time was the 87% for the 702 NPs and the
75% for the 705 NPs referred to the loaded amount. Again, the
higher MW of the lipophilic portion in the case of the 705 NPs
accounts for a more eﬃcient drug retention.
Finally, this study proved the ability of the proposed formu-
lation to entrap and sustainedly release a hydrophobic drug over
a time scale that is comparable to the NP residence time into the
body.56,57 Further, it elucidates the dependence of both drug
loading and drug release from the copolymer composition.4. Conclusion
N-(2-Hydroxypropyl)methacrylamide, known as non toxic, non
immunogenic and capable to be functionalized in mild condi-
tions, has been exploited to both synthesize a novel lipophilic
and biodegradable HPMA-CL5 macromonomer and to provide
steric stability to the NPs produced starting from this macro-
monomer. In particular, to obtain a well dened and tunable
structure for the lipophilic macromonomer, the adoption of an
inverse macromonomer method was necessary due to the low
reactivity of the HPMA as the co-catalyst in the ROP of cyclic
esters. This inverse macromonomer approach comprises threeThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinesteps: (i) the ROP of the 3-caprolactone in the presence of
a reactive primary alcohol (i.e. benzyl alcohol), (ii) the acylation
of the product with succinic anhydride and (iii) the DCC-
mediated esterication with the HPMA. On the other hand,
the direct ROP of the 3-caprolactone, using HPMA as the co-
catalyst, proved to lead to a poor HPMA conversion and hence
to a poor control over the nal macromonomer MW. Then, to
produce amphiphilic diblock copolymers able to self-assemble
in an aqueous environment forming stable NPs,
a poly(HPMA)70 macro-CTA was rstly synthesized via solution
RAFT polymerization in ethanol/acetic buﬀer mixture. This was
further chain extended with the HPMA-CL5 macromonomer to
obtain a comb-like polymer composed of a homogeneous pol-
y(HPMA) backbone and degradable oligo(caprolactone)
pendants. A simplied nanoprecipitation strategy to assemble
the nal block copolymer in monodisperse core–shell NPs was
also introduced. Since it was demonstrated that a high polymer
concentration (up to 20% w/w) in the organic phase does not
have a detrimental eﬀect on the NP size and PDI, this strategy is
promising in the production of ready-to-use nanovectors,
avoiding intermediate steps like lyophilization and dialysis. The
degradation kinetics of the produced NPs, as well as their ability
to encapsulate and mediate the release of a hydrophobic drug
was nally studied and related to the copolymer composition.Conﬂicts of interest
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